The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one of the world’s largest producers of vaccinations for a variety of conditions, including tetanus ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella, fears of job cuts and drug shortages have prompted a call for industrial action in the company ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. The FDA has approved Sarclisa ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.